BioAlliance suspends liver cancer trial

Following advice from the Drug Safety Monitoring Board, BioAlliance has suspended a Phase II/III trial of doxorubicin Transdrug for liver cancer. The drug did show clinical activity; however, it also resulted in "frequent and more severe pulmonary adverse events than expected," according to BioAlliance. Release

Suggested Articles

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.

RA Capital 's 15-month old inaugural venture fund that has already seen 25% of its portfolio companies IPO or be acquired.